

We Claim:-

1. A ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the *in vivo* tumour regression activity of the TNF is enhanced.
2. A ligand capable of binding to human TNF, the ligand being characterised in that when it binds to TNF the *in vivo* tumour regression activity of the TNF is enhanced; the ligand binding to the TNF such that the epitope of the TNF defined by the topographic region of residues 1-30, 117-128 and 141-153 is substantially prevented from binding to naturally occurring biologically active ligands.
- 5 3. A ligand which binds to human TNF in the topographic regions of residues 1-30, 117-128 and 141-153.
4. A ligand as claimed in claim 3 in which the ligand binds to human TNF in the topographic regions of residues 1-26, 117-128 and 141-153.
5. A ligand as claimed in claim 1 in which the ligand is selected from the group consisting of antibodies, F(ab) fragments, single domain antibodies (dABs) restructured antibodies, single chain antibodies and serum binding proteins.
6. A ligand as claimed in claim 5 in which the ligand is a monoclonal antibody or F(ab) fragment thereof.
7. A ligand as claimed in claim 1 in which the ligand is MAb 32 (ECACC 89080302).

8. A composition comprising TNF in combination with a ligand as claimed in claim 1 in which the ligand is bound to the TNF.